Skip to main content
Luye Pharma Group Limited logo

Luye Pharma Group Limited — Investor Relations & Filings

Ticker · 2186 HKEX Manufacturing
Open in API
Filings indexed 1,503 across all filing types
Latest filing 2026-01-05 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 2186

About Luye Pharma Group Limited

http://www.luye.cn

Luye Pharma Group is an international pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative medications, novel formulations, and biopharmaceutical products. The company's core strategy emphasizes advanced drug delivery systems, including microspheres, liposomes, and transdermal technologies, to enhance therapeutic efficacy and patient compliance. Luye Pharma maintains a strong focus on key therapeutic areas, particularly the Central Nervous System (CNS). Its portfolio includes proprietary products such as Roxinlin® (Toludesvenlafaxine extended-release tablets) and various long-acting injectable antipsychotic formulations, positioning the group as a global pharmaceutical enterprise.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' filed with the Hong Kong Exchanges and Clearing Limited. This is a standard regulatory filing required by the HKEX for listed companies to report monthly movements in securities, including share capital, issued shares, and treasury shares. It does not represent a specific corporate event like a dividend, M&A, or earnings release, but rather a recurring regulatory disclosure of capital structure changes. Therefore, it falls under the 'Regulatory Filings' category.
2026-01-05 English
Terms of Reference for Nomination Committee of the board of directors of the Company
Governance Information Classification · 1% confidence The document is titled 'Terms of Reference for Nomination Committee' for Luye Pharma Group Ltd. It outlines the purpose, composition, authority, and responsibilities of the company's Nomination Committee. This type of document falls under corporate governance policies, which define the internal rules and board structure of the company. According to the provided filing definitions, 'Governance Information' (CGR) is the appropriate category for reports detailing internal rules, board structure, and governance practices.
2025-12-31 English
APPOINTMENT OF NOMINATION COMMITTEE MEMBER
Board/Management Information Classification · 1% confidence The document is an official announcement from Luye Pharma Group Ltd. regarding the appointment of a new member to the company's Nomination Committee. This falls under the category of changes to the board or management structure.
2025-12-31 English
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Board/Management Information Classification · 1% confidence The document is a 'List of Directors and their Role and Function' for Luye Pharma Group Ltd. It details the composition of the Board of Directors and the membership of various board committees. This type of disclosure is a standard corporate governance filing that provides transparency regarding board structure and committee assignments, which falls under the Governance Information category.
2025-12-31 English
DISCLOSEABLE TRANSACTIONS TRANSFER OF 25% INTEREST IN NANJING LUYE AND RELATED TRANSACTIONS
Regulatory Filings Classification · 1% confidence The document is a formal announcement by Luye Pharma Group Ltd. regarding 'Disclosable Transactions' involving the transfer of a 25% interest in a subsidiary (Nanjing Luye) and related financial arrangements (put options, call options, and guarantees). It details the terms of the equity transfer agreement, listing rule implications, and financial obligations. This is a standard corporate announcement for a disclosable transaction under the Hong Kong Stock Exchange Listing Rules, which falls under the 'Regulatory Filings' category as it is a specific corporate event announcement that does not fit into the other specialized categories like M&A (which usually refers to full takeovers/mergers) or Earnings Releases.
2025-12-28 English
VOLUNTARY ANNOUNCEMENT THE GRANT OF EXCLUSIVE COMMERCIALIZATION RIGHTS TO NHWA FOR THREE LONG-ACTING INJECTABLE ANTIPSYCHOTICS IN THE CHINESE MAINLAND
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement from Luye Pharma Group Ltd. regarding a strategic commercialization agreement with Jiangsu Nhwa Pharmaceutical Co., Ltd. for three antipsychotic products. It details the nature of the partnership, the licensing fee, and the strategic rationale for the collaboration. This type of corporate development and business partnership announcement falls under the category of general regulatory filings (RNS) as it does not fit into specific categories like M&A (which typically involves ownership changes or takeovers) or other specialized financial reporting categories.
2025-12-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.